Dake Benjamin T. - 08 Dec 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
08 Dec 2022
Net transactions value
-$214,066
Form type
4
Filing time
12 Dec 2022, 17:00:23 UTC
Previous filing
08 Dec 2022
Next filing
14 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $21,400 +10,000 $2.14* 10,000 08 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $19,435 -928 -9.3% $20.94 9,072 08 Dec 2022 Direct F1, F2
transaction AVTE Common Stock Sale $58,302 -2,695 -30% $21.63 6,377 08 Dec 2022 Direct F1, F3
transaction AVTE Common Stock Sale $72,178 -3,199 -50% $22.56 3,178 08 Dec 2022 Direct F1, F4
transaction AVTE Common Stock Sale $76,533 -3,178 -100% $24.08 0 08 Dec 2022 Direct F1, F5
transaction AVTE Common Stock Options Exercise $843 +394 $2.14* 394 09 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $9,861 -394 -100% $25.03 0 09 Dec 2022 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -10,000 -4.6% $0.000000 208,030 08 Dec 2022 Common Stock 10,000 $2.14 Direct F1, F7
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -394 -0.19% $0.000000 207,636 09 Dec 2022 Common Stock 394 $2.14 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.235 to $21.22, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.25 to $22.20, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.27 to $22.845, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.43 to $24.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary